|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CN103030617A
(zh)
*
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
AU2006289093A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
EP2540725A1
(de)
|
2006-05-04 |
2013-01-02 |
Boehringer Ingelheim International GmbH |
Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
WO2008020011A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
WO2008034859A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
WO2008049923A1
(en)
*
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
WO2008101939A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CL2008002427A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
|
RS56990B1
(sr)
|
2007-09-10 |
2018-05-31 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
|
|
JP5498392B2
(ja)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
AU2009270936B2
(en)
|
2008-07-15 |
2014-12-18 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
AU2009286380B2
(en)
|
2008-08-28 |
2011-09-15 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
|
KR20110063447A
(ko)
|
2008-09-08 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
|
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
CN102256976A
(zh)
|
2008-12-23 |
2011-11-23 |
贝林格尔.英格海姆国际有限公司 |
有机化合物的盐形式
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
UY32427A
(es)
*
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
DK2396005T3
(da)
*
|
2009-02-13 |
2026-02-09 |
Boehringer Ingelheim Int |
Sglt2 hæmmer til at forbedre glykæmisk kontrol
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
JP5685550B2
(ja)
*
|
2009-02-13 |
2015-03-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
|
|
US20110014284A1
(en)
|
2009-02-13 |
2011-01-20 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
PT2414363E
(pt)
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
EP2451797B1
(en)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
|
|
MX2012003126A
(es)
|
2009-09-21 |
2012-06-19 |
Gilead Sciences Inc |
Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
|
|
PT2486029E
(pt)
|
2009-09-30 |
2015-10-14 |
Boehringer Ingelheim Int |
Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
|
|
EA020798B1
(ru)
|
2009-09-30 |
2015-01-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
HUE031375T2
(en)
|
2009-10-14 |
2017-07-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
RS53827B1
(sr)
|
2009-11-02 |
2015-06-30 |
Pfizer Inc. |
Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
|
SG10201506114UA
(en)
|
2010-05-11 |
2015-09-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
WO2012059416A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
EP2697218B1
(en)
|
2011-04-13 |
2016-05-25 |
Janssen Pharmaceutica NV |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
BR112013031032A2
(pt)
|
2011-06-03 |
2016-11-29 |
Boehringer Ingelheim Int |
inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130303446A1
(en)
|
2012-05-09 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
JP6218811B2
(ja)
|
2012-05-14 |
2017-10-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
EP4678242A3
(en)
|
2013-04-18 |
2026-03-18 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition, methods for treating and uses thereof
|
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
|
ES2969764T3
(es)
|
2013-12-17 |
2024-05-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
|
|
CN115671290A
(zh)
*
|
2014-01-23 |
2023-02-03 |
勃林格殷格翰动物保健有限公司 |
犬科动物中代谢紊乱的治疗
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
WO2015150299A2
(en)
|
2014-04-01 |
2015-10-08 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
CN103965020B
(zh)
*
|
2014-05-06 |
2015-09-09 |
启东东岳药业有限公司 |
制备5-碘-2-溴苄醇的方法
|
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖを治療するためのトール様受容体の調節因子
|
|
SG11201701520TA
(en)
|
2014-09-16 |
2017-04-27 |
Gilead Sciences Inc |
Solid forms of a toll-like receptor modulator
|
|
WO2016046150A1
(en)
|
2014-09-25 |
2016-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
|
KR102659761B1
(ko)
|
2015-08-27 |
2024-04-24 |
베링거잉겔하임베트메디카게엠베하 |
Sglt-2 억제제를 포함하는 액상 약제학적 조성물
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
DK3785717T3
(da)
|
2015-09-16 |
2022-03-21 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af coronaviridae-infektioner
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
|
KR20190084096A
(ko)
|
2016-11-10 |
2019-07-15 |
베링거 인겔하임 인터내셔날 게엠베하 |
약제학적 조성물, 치료 방법 및 이의 용도
|
|
US10682368B2
(en)
|
2017-03-14 |
2020-06-16 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
|
|
CA3059777C
(en)
|
2017-05-01 |
2023-02-21 |
Gilead Sciences, Inc. |
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
TWI810456B
(zh)
|
2019-05-22 |
2023-08-01 |
美商基利科學股份有限公司 |
Tlr7調節化合物及hiv疫苗之組合
|
|
EP4064854A1
(en)
|
2019-11-28 |
2022-10-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
|
|
AU2021222297B2
(en)
|
2020-02-17 |
2026-01-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
|
IL296035A
(en)
|
2020-03-06 |
2022-10-01 |
Vertex Pharma |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
KR20220153619A
(ko)
|
2020-03-12 |
2022-11-18 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 뉴클레오사이드의 제조 방법
|
|
CA3172483A1
(en)
|
2020-04-06 |
2021-10-14 |
Scott Ellis |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
|
PE20230618A1
(es)
|
2020-06-24 |
2023-04-14 |
Gilead Sciences Inc |
Analogos de nucleosido de 1'-ciano y usos de los mismos
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
US20240269105A1
(en)
|
2021-07-28 |
2024-08-15 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
JP2024525981A
(ja)
|
2021-07-28 |
2024-07-12 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
JP2024527434A
(ja)
|
2021-07-28 |
2024-07-24 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
US20250170128A1
(en)
|
2021-12-30 |
2025-05-29 |
NEWAMSTERDAM PHARMA B.V. (Dutch Chamber of Commerce No. 5597 1946) |
Obicetrapib and SGLT2 Inhibitor Combination
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
AU2023277704A1
(en)
|
2022-05-25 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
EP4676494A1
(en)
|
2023-03-06 |
2026-01-14 |
Boehringer Ingelheim Vetmedica GmbH |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
|
KR20260019532A
(ko)
|
2023-05-24 |
2026-02-10 |
베링거잉겔하임베트메디카게엠베하 |
하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
|
|
US20240390317A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|